Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Sells 29,102 Shares

Posted by Patrick Bannon on Apr 3rd, 2025

Abrdn Life Sciences Investors (NYSE:HQL – Get Free Report) major shareholder Saba Capital Management, L.P. sold 29,102 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $12.28, for a total transaction of $357,372.56. Following the completion of the sale, the insider now owns 3,141,682 shares of the company’s stock, valued at approximately $38,579,854.96. The trade was a 0.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.58, for a total transaction of $611,677.34.
On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.01, for a total value of $428,315.22.
On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.62, for a total value of $2,724.00.
On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total value of $502,370.00.
On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.95, for a total value of $599,668.65.
On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.03, for a total transaction of $25,899.38.
On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.27, for a total transaction of $216,090.61.
On Wednesday, January 29th, Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.12, for a total transaction of $164,836.88.

Abrdn Life Sciences Investors Stock Down 1.0 %

NYSE:HQL traded down $0.12 during mid-day trading on Thursday, reaching $12.19. 99,299 shares of the company’s stock traded hands, compared to its average volume of 99,230. The company has a 50 day moving average price of $13.47 and a 200-day moving average price of $14.04. Abrdn Life Sciences Investors has a 12-month low of $12.14 and a 12-month high of $15.90.

Abrdn Life Sciences Investors Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Friday, February 21st were issued a dividend of $0.47 per share. The ex-dividend date was Friday, February 21st. This represents a $1.88 dividend on an annualized basis and a dividend yield of 15.42%.

Institutional Trading of Abrdn Life Sciences Investors

Large investors have recently added to or reduced their stakes in the stock. Absolute Investment Advisers LLC bought a new position in Abrdn Life Sciences Investors in the 4th quarter worth $5,242,000. Sanctuary Advisors LLC raised its stake in Abrdn Life Sciences Investors by 11.4% in the third quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock worth $183,000 after buying an additional 1,355 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Abrdn Life Sciences Investors in the fourth quarter worth about $3,129,000. Wolverine Asset Management LLC bought a new stake in Abrdn Life Sciences Investors during the 4th quarter valued at approximately $1,594,000. Finally, Steward Partners Investment Advisory LLC raised its position in shares of Abrdn Life Sciences Investors by 379.8% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,860 shares of the company’s stock worth $64,000 after acquiring an additional 3,847 shares in the last quarter. Institutional investors own 32.21% of the company’s stock.

About Abrdn Life Sciences Investors

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.